Investing
Cathie Wood's ARK Invest Buys Over 530,000 Shares of Fate Therapeutics
Published:
One of the ARK Invest exchange-traded funds run by ETF star Cathie Wood made a sizable purchase on Wednesday. The fund bought over 530,000 shares of Fate Therapeutics Inc. (NASDAQ: FATE), as the price of this ETF was down over 2% on the day. Note that this fund is up significantly in the past year.
Specifically, ARK Innovation ETF (NYSEARCA: ARKK) bought 535,305 shares of Fate Therapeutics. At Wednesday’s closing price, this would have valued this purchase at roughly $46.2 million. Even though this is a small fraction of the total holdings, every little bit counts. The fund is up 60% in the past year.
Here’s a look at the other purchases across the ARK ETFs:
| Fund | Ticker | Company | Shares |
|---|---|---|---|
| ARKF | PATH | UiPath | 279,284 |
| ARKG | SGFY | Signify Health | 53,916 |
| ARKG | RXRX | Recursion Pharmaceuticals | 204,752 |
| ARKG | RPTX | Repare Therapeutics | 18,190 |
| ARKG | QSI | Quantum-Si | 359,389 |
| ARKG | MASS | 908 Devices | 47,945 |
| ARKK | FATE | Fate Therapeutics | 535,305 |
| ARKK | COIN | Coinbase Global | 20,165 |
| ARKK | TSLA | Tesla | 110,731 |
| ARKQ | PATH | UiPath | 135,228 |
| ARKW | VUZI | Vuzix | 521,151 |
| ARKW | FTCH | Farfetch | 599,955 |
| ARKX | AVAV | Aerovironment | 23,098 |
| ARKX | PATH | UiPath | 25,645 |
Catherine Wood, the CEO and CIO of ARK Investment Management, is a minority and nonvoting shareholder of 24/7 Wall St.
24/7 Wall St.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
